Image pharmaphorum Editor Views & Analysis Nine for 2019: how did we do on our predictions, and what do... Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. Views & Analysis Deep Dive: Patient Engagement Patient engagement has moved from a lofty goal to a tangible part of most pharma companies’ businesses – but there are still many untapped areas where the industry can harness this transfor Views & Analysis Real-world or real evidence? There was a time when the distinction between data from clinical trials and data from any other source was clear. White Papers Sponsored The next decade of clinical trials innovation Clinical trials have not fundamentally changed over the past 20 years, but there have been signs that practices are slowly evolving. Load more results
Views & Analysis Nine for 2019: how did we do on our predictions, and what do... Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead.
Views & Analysis Deep Dive: Patient Engagement Patient engagement has moved from a lofty goal to a tangible part of most pharma companies’ businesses – but there are still many untapped areas where the industry can harness this transfor
Views & Analysis Real-world or real evidence? There was a time when the distinction between data from clinical trials and data from any other source was clear.
White Papers Sponsored The next decade of clinical trials innovation Clinical trials have not fundamentally changed over the past 20 years, but there have been signs that practices are slowly evolving.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
